Anti-Mouse CD103 (ITGAE) – Dylight® 650

This CD103 antibody was produced using recombinant mouse CD103

This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.

Red Laser (652 nm)

Anti-CD103 antibody (clone 2E7) activity is directed against mouse CD103 (αE integrin).

CD103 is expressed on intraepithelial lymphocytes, mucosa- and epithelial associated T lymphocytes, various populations of dendritic cells, dendritic epidermal T cells, some TGF β1 cells, and subsets of peripheral T cells, innate lymphoid cells, mast cells, and thymocytes.

CD103 integrin is a heterodimeric transmembrane receptor formed by the dimerization of α_E (CD103) with β₇^1,2. CD103 plays a role in intestinal homeostasis and inflammation³, is a key molecule in T cell activation¹, and also functions within the tumor microenvironment¹. CD103 integrin plays a role in the anti-tumor activities of tissue resident memory T cells (T_RM), a type of memory T cell that is part of the adaptive immune system and also protects human epithelial tissues against inflammatory and infectious disease¹. TRM are defined by expression of CD103 and CD49a integrins and the C-type lectin CD69¹. Additionally, CD103 is recruited at the immune synapse formed between cytotoxic T lymphocytes and epithelial tumor cells¹, is required for polarized exocytosis of lytic granules leading to target cell lysis¹, and migratory CD103⁺ dendritic cells are important for the initiation of cytotoxic T cell responses⁴.

CD103 integrin binds to E-cadherin^1,2. TGFβ increases the affinity of CD103 for E-cadherin through phosphorylation of integrin-linked kinase, induces CD103 on TCR-engaged antigen-specific CD8⁺ T cells, and is also directly involved in CD103 activation.

The 2E7 clone was originally used to define CD103 integrin expression in lymphocyte subsets and during T cell ontogeny⁵. 2E7 was shown to be reactive against CD103 integrin by immunoprecipitation.

E-Cadherin

1. Mami-Chouaib F, Blanc C, Corgnac S, et al. J Immunother Cancer. 6(1):87. 2018.
2. Hoffmann JC, Schön MP. Cancers (Basel). 13(24):6211. 2021.
3. Jaensson E, Uronen-Hansson H, Pabst O, et al. J Exp Med. 205(9):2139-2149. 2008.
4. Hong Y, Kim YK, Kim GB, et al. J Extracell Vesicles. 8(1):1670893. 2019.
5. Lefrançois L, Barrett TA, Havran WL, et al. Eur J Immunol. 24(3):635-640. 1994.
6. Mysorekar IU, Lorenz RG, Gordon JI. J Biol Chem. 277(40):37811-37819. 2002.
7. Xiao B, Wang Y, Reinach PS, et al. PLoS One. 10(1):e0115333. 2015.
8. Sierro F, Evrard M, Rizzetto S, et al. Immunity. 47(2):374-388.e6. 2017.
9. Bedoui S, Whitney PG, Waithman J, et al. Nat Immunol. 10(5):488-495. 2009.
10. Edelson BT, KC W, Juang R, et al. J Exp Med. 207(4):823-836. 2010.
11. del Rio ML, Cote-Sierra J, Rodriguez-Barbosa JI. Transpl Int. 24(5):501-513. 2011.
12. Mikami N, Matsushita H, Kato T, et al. J Immunol. 186(12):6886-6893. 2011.
13. Mackay LK, Rahimpour A, Ma JZ, et al. Nat Immunol. 14(12):1294-1301. 2013.
14. Quinn KM, Yamamoto A, Costa A, et al. J Immunol. 191(10):5085-5096. 2013.
15. Blankenhaus B, Reitz M, Brenz Y, et al. PLoS Pathog. 10(2):e1003913. 2014.
16. Iwata A, Kawashima S, Kobayashi M, et al. Int Immunol. 26(2):103-114. 2014.
17. Guo X, Tanaka Y, Kondo M. Immunol Lett. 163(1):40-48. 2015.
18. Lee LM, Ji M, Sinha M, et al. PLoS One. 11(12):e0167693. 2016.
19. Herndler-Brandstetter D, Ishigame H, Shinnakasu R, et al. Immunity. 48(4):716-729.e8. 2018.
20. Tordesillas L, Lozano-Ojalvo D, Dunkin D, et al. Nat Commun. 9(1):5238. 2018.
21. Ge C, Monk IR, Pizzolla A, et al. Cell Rep. 29(13):4236-4244.e3. 2019.
22. Nelson CE, Thompson EA, Quarnstrom CF, et al. Cell Rep. 17;28(12):3092-3104.e5. 2019.
23. Niven J, Madelon N, Page N, et al. Cell Rep. 28(1):21-29.e6. 2019.
24. Sasaki K, Himeno A, Nakagawa T, et al. Nat Commun. 10(1):3878. 2019.
25. Yue X, Lio CJ, Samaniego-Castruita D, et al. Nat Commun. 10(1):2011. 2019.
26. Hassan AO, Kafai NM, Dmitriev IP, et al. Cell. 183(1):169-184.e13. 2020.